#1 Clinical Trials Search in Europe

A Study to Evaluate the Safety and Effectiveness of Ritlecitinib Tosilate in Adults with Moderate to Severe Hidradenitis Suppurativa

2 1

What is this study about?

This study focuses on individuals living with Hidradenitis Suppurativa, a chronic skin condition characterized by painful, red lumps under the skin that can form abscesses or tunnels. The purpose of the study is to evaluate the safety and effectiveness of a medication called ritlecitinib, also known as PF-06651600, compared to a placebo.

During the study, participants will be assigned to receive either the active medication or a placebo in a randomized way, meaning the group assignment is decided by chance. The process is double-blind, which means neither the participants nor the researchers know which substance is being administered. The study will last for a total of 16 weeks, during which time the effects of the treatment on the skin and symptoms will be monitored.

Who Can Join the Study?

  • You must be between 18 and 75 years old.
  • You must have a confirmed medical diagnosis of Hidradenitis Suppurativa (a chronic skin condition that causes painful lumps under the skin) for at least 6 months.
  • Your condition must be moderate to severe, which means you have Hurley Stage II or III (levels used to describe how much the skin is affected by the disease) and at least 5 inflammatory lesions (painful, red, swollen bumps like abscesses or nodules) located in at least 2 different body areas.
  • You must have either not seen enough improvement after taking systemic therapy (medicine that travels through the entire body, such as a pill) for at least 4 weeks, or you must have a medical reason why you cannot take this type of medicine.

Who Cannot Join the Study?

  • Having 20 or more draining fistulas, which are abnormal tunnels or passages that form under the skin and leak fluid.
  • Having other skin conditions that might make it difficult to tell if the treatment is working for your specific condition.
  • Having previously used a JAK inhibitor or a BTK inhibitor, which are types of medicines used to change how the immune system works.
  • Having any serious medical or mental health illnesses.
  • A limited number of people in the study may have previously used anti-TNF-α, IL-17 inhibitors, or IL-23 inhibitors, which are specific types of medications used to calm an overactive immune system.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name City Country Status
Center For Pediatric And Adolescent Medicine Of The Johannes Gutenberg University Mainz Mainz Germany
Technische Universitaet Dresden Dresden Germany
Dermedic Jacek Zdybski Ostrowiec Swietokrzyski Poland
Royalderm Agnieszka Nawrocka Warsaw Poland

Other Sites

Site Name City Country Status
Hospital General Universitario Gregorio Maranon Madrid Spain
Gpdblfh Uokywxnwtb Hbdlvqtv Oi Lfgintm Larissa Greece
Cugfypdlwm Pwxgnjdvqqx Lszmplthorqlwvedscuuwim Mojidfis sageg Wroclaw Poland
Aacauf Mkjnamx Cdllvq Slax Thessaloniki Greece
Udhownhkfeajdjmzpnkbu Wltoglzyl Ach Wuerzburg Germany
Unkbzumtdg Mnujkuv Cgoskp Hlfwncxajnydgafzp Hamburg Germany
Uvsgxujutjadwfhumvgps Sffolwxdktyppfdihx Axc Kiel Germany
Cwmnhhf Baghd Knmzfzonqlo Pfivgvem Swa z oktr Gdansk Poland
Cufxsgsp Hgratfonyizs Ulrwcjphnccmv Dm Pbwiaqpyto Pontevedra Spain
Uqulxfgmse Gcxfysk Htdkwyev Os Hldycuczj Heraklion Greece
Hsgorequ Utakxceqnauct Vyvtnx Dt Lio Nyttpf Granada Spain
Kntfszs Asvnrpxvb Sns z odcb Warsaw Poland
Ulwrgzipbt Gkoboto Hrepnvzi Alvhbmy Gvptjsn Hovxsbuo Om Wdio Ayebzc H Atmr Vfkkkus Chaidari Greece
Ulwlpihbsxzux Sdzvveh Khusumatg Iwaztdgvxzxe Cjfjoct W Renbtgmrq Rzeszow Poland
Gbsxkvh Htagbjdc Ot Tqapzwtzrxib Pztajyyqyczx Thessaloniki Greece
Tifxupvi Sbu z ousd Piotrkow Trybunalski Poland
Sfdt Sioi Mqbutgs Chmqcn Dz Eosqgefe Wtbuoiramokwom Wroclaw Poland
Amdimin Stawyct Hahwcynr Oa Vcepfkgw Aly Dekbwmkdzrbdpo Dtlnbjne Athens Greece
Pgcjggtpt Iybqkbas Mccbaunx Mkbazswdfebm Sihyb Wfgzyzoswhtn I Aucaadlgftyku Warsaw Poland
Gczejk Uwdwmwychs Fpczamzoo Frankfurt Germany
Cufdzlp Zqdlvbr Dfilcpw I Rwnllrb Icw Jhvv Pzvui Ia W Sewgwepc Svf z ooqa Sosnowiec Poland
Hyjimlcp Uaohseubojpfz Pqxxfk Dnn Mxp Cadiz Spain
Tlmsx Pxtbpwoheyj Snemonwcmcom Crqaqzz Mfgzpihp Sjj z oywu Szczecin Poland

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Germany Germany
Not recruiting
21.04.2026
Greece Greece
Not recruiting
21.04.2026
Poland Poland
Not recruiting
21.04.2026
Spain Spain
Not recruiting
21.04.2026

Trial locations

Ritlecitinib is an oral medication taken in capsule form that is being tested to see if it can help reduce the symptoms and improve the skin condition in adults living with moderate to severe hidradenitis suppurativa.

Hidradenitis suppurativa – This is a chronic skin condition that causes painful lumps to form underneath the skin. These lumps typically appear in areas where skin rubs together, such as the armpits or groin. As the condition progresses, these lumps can break open and drain fluid or pus. Over time, the inflammation may lead to the formation of tunnels or tracts under the skin. These connections can link multiple lumps together and cause scarring. The disease often occurs in recurring episodes.

Trial ID:
2025-522705-37-00
Protocol code:
B7981119
NCT ID:
NCT07228390
Trial Phase:
Therapeutic exploratory (Phase II)

Other Trials to Consider

  • A study to evaluate the effectiveness and safety of LAD328 in adults with moderate to severe hidradenitis suppurativa

    Recruiting

    2 1 1
    Investigated Diseases:
    Investigated Drugs:
    Bulgaria France Germany Poland Spain

  • A study to evaluate the effectiveness and safety of BFB759 in adults with moderate to severe hidradenitis suppurativa

    Recruiting

    2 1
    Bulgaria Czechia Germany Poland Spain